O80: GREMLIN-1 PROMOTES TUMOURIGENESIS AND METASTASIS IN HER2 POSITIVE BREAST CANCER

Abstract Introduction HER2 over-expression denotes poor prognosis in breast cancers.Bone morphogenetic protein(BMP) signalling is known to interact with EGF signalling, co-regulating cancer progression.BMP antagonist Gremlin-1 may influence disease progression, but this remains unexplored positive cancers. Method GREM1 and expression, clinical outcomes were examined cohorts.GREM1 overexpression or pEF control plasmid transduced into BT474 HER2+breast cells. In vitro function tests using BT474GREM1cells include 2D/3D growth, migration, expression of epithelial mesenchymal transition(EMT)markers. Signalling cascades treated RhGremlin-1. vivo, BALB/c nude mice underwent either mammary injection intra-cardiac BT474pEF BT474GREM1 cells burden assessed. Result correlates tumours(p=0.03) higher metastatic cancers (p = 0.04). patients high have survival(p 0.0002). up-regulated markers EMT compared control. RhGremlin-1 active AKT pathway independent BMP signalling. vitro, significantly proliferate migrate control(p<0.05 p < 0.001).This confirmed grew larger tumours(p<0.05) had more PETCT hotspots. Conclusion correlated promotes cellular migration metastasis.Gremlin-1 a novel area research potential as prognostic biomarker therapeutic target for personalised, effective, outcomes. Take-home message antagonists are gaining interest their therapeutics.This shows importance DRAGONS DEN